Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
118 results
- ABCSG-18Independent statistical analysis of ABCSG-18, a randomized phase 3 trial of denosumab in patients with breast cancer receiving aromatase inhibitor therapy, including trial design, fracture, bone mineral density, disease-free survival, bone metastases-free…
- ACCELERATEComplete statistical analysis of ACCELERATE (NCT01687998), a randomized phase 3 study of evacetrapib versus placebo in high-risk vascular disease, including trial design, composite cardiovascular endpoints, Cox modeling, ANOVA, confidence intervals, p-values, and…
- AIM-HIGHIndependent statistical analysis of AIM-HIGH, the randomized phase 3 trial of extended-release niacin plus simvastatin versus placebo plus simvastatin for prevention of vascular events, including its time-to-event endpoints, Cox model, hazard ratios,…
- ALTTOIndependent statistical analysis of the phase 3 ALTTO trial of lapatinib and trastuzumab in breast neoplasms, covering randomized trial design, disease-free survival, overall survival, recurrence endpoints, safety, and time-to-event methodology.
- APPRAISE-2Independent statistical analysis of APPRAISE-2, the randomized phase 3 trial of apixaban versus placebo in acute coronary syndrome, including time-to-event endpoints, Cox models, hazard ratios, confidence intervals, p-values, and safety results.
- ARCHESComplete statistical analysis of the ARCHES phase 3 trial of enzalutamide plus androgen deprivation therapy versus placebo plus ADT in metastatic hormone sensitive prostate cancer, including rPFS, overall survival, secondary endpoints, statistical…
- ARIEL3Independent statistical analysis of the phase 3 ARIEL3 trial of rucaparib as switch maintenance after platinum in relapsed high-grade serous or endometrioid ovarian cancer, including trial design, progression-free survival, Cox modeling, hazard…
- ARIEL4Independent statistical analysis of ARIEL4, a randomized phase 3 trial of rucaparib versus chemotherapy in patients with BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer, including time-to-event endpoints, Cox models, hazard ratios,…
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- ASSUREIndependent statistical analysis of the ASSURE phase 3 trial of sunitinib malate or sorafenib tosylate in patients with kidney cancer removed by surgery, including disease-free survival, overall survival, statistical methodology, interpretation, and…
- ATMOSPHEREIndependent statistical analysis of the ATMOSPHERE phase 3 trial of aliskiren and aliskiren/enalapril in chronic heart failure, including trial design, time-to-event endpoints, Cox modeling, non-inferiority, superiority, safety, and interpretation.
- BEAUTIFULIndependent statistical analysis of the phase 3 BEAUTIFUL trial of ivabradine versus placebo in patients with stable coronary artery disease and left ventricular systolic dysfunction, including its composite primary endpoint, time-to-event methods,…
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- CARMELINAIndependent statistical analysis of CARMELINA (NCT01897532), a randomized phase 4 trial of linagliptin versus placebo in patients with type 2 diabetes mellitus, including time-to-event methodology, non-inferiority testing, cardiovascular and renal endpoints, safety,…
- CAROLINAIndependent statistical analysis of the CAROLINA phase 3 trial comparing linagliptin with glimepiride in patients with type 2 diabetes, including non-inferiority testing, cardiovascular outcomes, glycaemic control, ANCOVA, Cox regression, and logistic regression.
- CATNONIndependent statistical analysis of CATNON (NCT00626990), a randomized phase 3 trial evaluating concomitant and adjuvant temozolomide in anaplastic glioma without 1p/19q loss of heterozygosity.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-037Independent statistical analysis of CheckMate-037, a randomized phase 3 trial of BMS-936558 (nivolumab) versus Investigator's Choice in unresectable or metastatic melanoma.
- CheckMate-078Independent statistical analysis of CheckMate-078, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated advanced or metastatic non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-274Independent statistical analysis of CheckMate-274 (NCT02632409), a randomized phase 3 trial of nivolumab versus placebo following surgery for bladder or upper urinary tract cancer, including its disease-free survival endpoints, Cox model results,…
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-76KComplete statistical analysis of CheckMate-76K, the randomized phase 3 trial of nivolumab versus placebo for prevention of recurrent melanoma after complete resection of stage IIB/C melanoma.
- COMPARZIndependent statistical analysis of the COMPARZ phase 3 trial comparing pazopanib with sunitinib in locally advanced and/or metastatic renal cell carcinoma, including its progression-free survival endpoint, non-inferiority framework, Cox model, and reported…
- CREDENCEComplete statistical analysis of CREDENCE, the randomized phase 3 trial evaluating canagliflozin versus placebo for renal and cardiovascular outcomes in participants with type 2 diabetes and diabetic nephropathy.
- DAPA-CKDIndependent statistical analysis of the randomized phase 3 DAPA-CKD trial evaluating dapagliflozin versus placebo for renal and cardiovascular outcomes in patients with chronic kidney disease.
- DAPA-HFIndependent statistical analysis of the DAPA-HF phase 3 trial evaluating dapagliflozin in patients with chronic heart failure with reduced ejection fraction, including trial design, endpoints, Cox models, win ratio, rate ratio, results,…
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- E5103Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast cancer.
- EINSTEIN-DVTIndependent statistical analysis of EINSTEIN-DVT, a randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with venous thrombosis, including its non-inferiority analysis, Cox model, hazard ratio, confidence interval,…
- EINSTEIN-PEIndependent statistical analysis of EINSTEIN-PE, the randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with acute symptomatic pulmonary embolism, including non-inferiority methodology, Cox analysis, hazard ratios, bleeding,…
- ELIXAIndependent statistical analysis of the ELIXA phase 3 trial of lixisenatide versus placebo in patients with acute coronary syndrome and type 2 diabetes, including its time-to-event endpoint, non-inferiority framework, hazard ratio, confidence…
- EMPA-REG OUTCOMEComplete statistical analysis of EMPA-REG OUTCOME, the randomized phase 3 trial of empagliflozin in patients with type 2 diabetes mellitus, including its time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority framework, cardiovascular outcomes, microvascular…
- EMPEROR-PreservedA detailed statistical analysis of EMPEROR-Preserved, the randomized phase 3 trial of 10 mg empagliflozin versus placebo in patients with heart failure, including time-to-event outcomes, Cox models, recurrent-event analysis, MMRM, and interpretation.
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ENVISAGE-TAVI AFComplete statistical analysis of ENVISAGE-TAVI AF, the randomized phase 3 trial comparing an edoxaban-based regimen with a vitamin K antagonist-based regimen in patients with atrial fibrillation after catheter-based heart valve replacement.
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- EXSCELA detailed independent statistical analysis of EXSCEL, the phase 3 trial of exenatide once weekly versus placebo in patients with type 2 diabetes mellitus, including its randomized design, time-to-event endpoints, Cox models,…
- ExteNETIndependent statistical analysis of the phase 3 ExteNET trial of neratinib after adjuvant trastuzumab in women with early stage breast cancer, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, survival methodology,…
- FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.
- FIRSTANAIndependent statistical analysis of the randomized phase 3 FIRSTANA trial of cabazitaxel versus docetaxel, both with prednisone, in patients with metastatic castration-resistant prostate cancer.
- FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…